JMP maintains "Market Outperform" rating and $6 price target on Nuvation for IBTROZI launch

From Yahoo Finance: 2025-06-29 03:03:00

Nuvation Bio Inc. (NYSE:NUVB) is rated as one of the best healthcare penny stocks to buy by analysts. JMP Securities analyst Silvan Tuerkcan maintains a “Market Outperform” rating on NUVB and a $6.00 price target per share for IBTROZI launch plans.

The FDA approved Nuvation’s cancer treatment IBTROZI for adults with ROS1-positive NSCLC. China’s NMPA also approved it for the same indication. IBTROZI is priced at $29,844 per month and has a two-year lead over competitor zidesamtinib for ROS1-positive NSCLC treatment.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focusing on developing targeted cancer therapies. Its lead product is IBTROZI, with pipeline candidates like safusidenib, NUV-1511, and NUV-868 targeting various tumors.

While NUVB shows investment potential, other AI stocks may offer greater upside. For a free report on the best short-term AI stock with significant growth potential, consider looking into AI stocks that benefit from Trump-era tariffs and the onshoring trend.

Read more: JMP Maintains “Market Outperform” on Nuvation (NUVB) for IBTROZI Launch Plans